Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

CDKN1C anticorps

CDKN1C Reactivité: Humain WB Hôte: Souris Monoclonal A120-1 unconjugated
N° du produit ABIN967507
  • Antigène Voir toutes CDKN1C Anticorps
    CDKN1C (Cyclin-Dependent Kinase Inhibitor 1C (p57, Kip2) (CDKN1C))
    Reactivité
    • 97
    • 53
    • 22
    • 2
    Humain
    Hôte
    • 64
    • 34
    Souris
    Clonalité
    • 63
    • 35
    Monoclonal
    Conjugué
    • 48
    • 7
    • 5
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Cet anticorp CDKN1C est non-conjugé
    Application
    • 40
    • 38
    • 34
    • 30
    • 22
    • 14
    • 14
    • 12
    • 8
    • 5
    • 4
    • 2
    • 1
    • 1
    Western Blotting (WB)
    Marque
    BD Pharmingen™
    Attributs du produit
    1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
    2. Please refer to us for technical protocols.
    3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
    Purification
    The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
    Immunogène
    p57[Kip2] Recombinant Human
    Clone
    A120-1
    Isotype
    IgG1 kappa
    Top Product
    Discover our top product CDKN1C Anticorps primaire
  • Indications d'application
    Applications for clone A120-1 include western blot analysis (1-2 µg/ml). SJCRH30 human rhabdomyosarcoma cells are suggested as a positive control (ATCC CRL-2061).
    Commentaires

    Related Products: ABIN967389

    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    0.5 mg/mL
    Buffer
    Aqueous buffered solution containing ≤0.09 % sodium azide.
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    4 °C
    Stockage commentaire
    Store undiluted at 4°C.
  • Graña, Reddy: "Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)." dans: Oncogene, Vol. 11, Issue 2, pp. 211-9, (1995) (PubMed).

    Lee, Reynisdóttir, Massagué: "Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution." dans: Genes & development, Vol. 9, Issue 6, pp. 639-49, (1995) (PubMed).

    Matsuoka, Edwards, Bai, Parker, Zhang, Baldini, Harper, Elledge: "p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene." dans: Genes & development, Vol. 9, Issue 6, pp. 650-62, (1995) (PubMed).

  • Antigène
    CDKN1C (Cyclin-Dependent Kinase Inhibitor 1C (p57, Kip2) (CDKN1C))
    Autre désignation
    p57 Kip2 (CDKN1C Produits)
    Synonymes
    anticorps BWCR, anticorps BWS, anticorps KIP2, anticorps WBS, anticorps p57, anticorps p57Kip2, anticorps cb961, anticorps p27Xic1-a, anticorps zgc:86618, anticorps AL024410, anticorps CDKI, anticorps Kip2, anticorps p57(kip2), anticorps p57KIP2, anticorps cyclin dependent kinase inhibitor 1C, anticorps cyclin-dependent kinase inhibitor 1Ca, anticorps cyclin-dependent kinase inhibitor 1C (P57), anticorps cyclin-dependent kinase inhibitor 1C, anticorps CDKN1C, anticorps cdkn1ca, anticorps Cdkn1c
    Sujet
    Cyclin dependent kinase inhibitors (CdkIs) inhibit progression through the cell cycle by binding to cyclins, Cdks, or cyclin-Cdk complexes. CdkIs are classified into two groups based on protein structure. p57[Kip2] belongs to a group that also includes p27[Kip1] and p21 (also known as Sdi1, Cip1, Waf1 and Pic1). Members of this group have a homologous amino-terminal Cdk inhibitory domain. Members of the second group [p16 (INK4A), p15 (INK4B), p18 (INK4C), and p19 (INK4D)] contain ankyrin repeat motifs. p57[Kip2] is a potent, tight-binding inhibitor of several G1 and S phase cyclin-Cdk complexes including cyclin E-Cdk2, cyclin D2-Cdk4, and cyclin A-Cdk2. It inhibits the mitotic cyclin B1-Cdk1 complex to a lesser extent. mRNA studies suggest that p57[Kip2] expression is tissue-specific, the highest levels have been found in embryonic and adult skeletal muscle, heart, kidney, lung, eye and brain. This is in contrast to the widespread tissue expression of p27[Kip1] and p21 mRNA. The expression of p57[Kip2] to primarily terminally differentiated cells suggests that p57[Kip2] may play a specialized role in cell cycle control. Clone A120-1 reacts with human p57[Kip2]. Recombinant human p57[Kip2] was used as immunogen.
    Poids moléculaire
    57 kDa
    Pathways
    Cycle Cellulaire, Dopaminergic Neurogenesis
Vous êtes ici:
Support technique